These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1244020)

  • 1. Acetylating phenotype of sulphonamides.
    Anwar N; Islam N; Choudhury AK
    Bangladesh Med Res Counc Bull; 1975 Oct; 1(2):120-6. PubMed ID: 1244020
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in acetylator phenotype over the lifespan in the Wistar rat.
    Lares-Asseff I; Camacho GA; Guillé AJ; Toledo AR; Trujillo F; Reyes RE; Juárez HM; Pérez G
    Mech Ageing Dev; 2006 Jan; 127(1):73-8. PubMed ID: 16298418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute urinary tract infection with low doses of sulfadiazine.
    Seppänen J
    Ann Clin Res; 1980; (25):19-24. PubMed ID: 7377745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of low dose sulfadiazine in patients with renal failure.
    Seppänen J; Viranta M; Julkunen R; Wilén G
    Ann Clin Res; 1980; (25):31-7. PubMed ID: 7377747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion and plasma levels of sulphonamides in patients with renal impairment.
    Adam WR; Dawborn JK
    Australas Ann Med; 1970 Aug; 19(3):250-4. PubMed ID: 4919245
    [No Abstract]   [Full Text] [Related]  

  • 6. [General acetylating capacity of the body of patients with rosacea].
    Alekseev IuV; Gladkikh SP; Mashkilleĭson AL; Altynbaeva RD; Evstaf'eva OL
    Vestn Dermatol Venerol; 1985 Oct; (10):21-2. PubMed ID: 2934906
    [No Abstract]   [Full Text] [Related]  

  • 7. Sulfadiazine handling in the rabbit. II. Mechanisms of nonlinear kinetics of elimination.
    du Souich P; McLean AJ; Lalka D; Vicuna N; Chauhuri E; McNay JL
    J Pharmacol Exp Ther; 1978 Oct; 207(1):228-35. PubMed ID: 702344
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduced sulfadiazine dose in the treatment of acute urinary tract infection in children.
    Anttila R; Julkunen R; Seppänen J
    Ann Clin Res; 1980; (25):25-9. PubMed ID: 7377746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of sulfadiazine upon different routes of administration in the rabbit.
    Ermi W; Ritschel WA
    Pharm Acta Helv; 1976; 51(11):326-30. PubMed ID: 1019175
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of the acetylating capacity of normals and diabetics with and without retinopathy.
    MAENGWYN-DAVIS GD; BECKER B; ROSEN DA; FRIEDENWALD JS
    Bull Johns Hopkins Hosp; 1955 Apr; 96(4):150-3. PubMed ID: 14364006
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and clinical experiences of sulfadiazine in low doses alone and in combination with trimethoprim.
    Seppänen J
    Ann Clin Res; 1980; (25):4-18. PubMed ID: 7377749
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of trimethoprim and sulfadiazine in the dog: urine concentrations after oral administration.
    Sigel CW; Ling GV; Bushby SR; Woolley JL; DeAngelis D; Eure S
    Am J Vet Res; 1981 Jun; 42(6):996-1001. PubMed ID: 7283250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of pharmacokinetic models for sulfonamides in food animals: metabolic depletion profile of sulfadiazine in the calf.
    Woolley JL; Sigel CW
    Am J Vet Res; 1982 May; 43(5):768-74. PubMed ID: 7091837
    [No Abstract]   [Full Text] [Related]  

  • 14. Metabolism of sulfanilamide and related drugs in isolated rat and rabbit liver cells.
    Suolinna EM
    Drug Metab Dispos; 1980; 8(4):205-7. PubMed ID: 6105051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and urinary excretion of sulfadiazine in buffalo calves.
    Jain SK; Uppal RP; Garg BD
    Ann Rech Vet; 1992; 23(4):389-93. PubMed ID: 1476408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and clinical experiences of the combination sulfadiazine-trimethoprim in the short-term treatment of acute urinary tract infections.
    Seppänen J; Ylitalo P; Julkunen R; Räisänen S; Masar SE
    Ann Clin Res; 1980; (25):39-45. PubMed ID: 7377748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators.
    Mattila MJ; Tiitinen H; Alhava E
    Ann Med Exp Biol Fenn; 1969; 47(4):308-15. PubMed ID: 5384058
    [No Abstract]   [Full Text] [Related]  

  • 19. [Acetylation phenotype in Graves' disease].
    Górnik W; Syrenicz A; Gawrońska-Szklarz B; Wójcicki J
    Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):743-5. PubMed ID: 2641798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
    Grant DM; Mörike K; Eichelbaum M; Meyer UA
    J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.